Last year, the National Institutes of Health (NIH) was shocked to find that dozens of scientists had run afoul of ethical restrictions and were making a great deal of outside income from private consulting deals with drug and biotechnology companies. New ethics rules, put in place after last year’s discovery, now bans all outside income from such companies. Nearly 40% of the scientists conducting hands-on research at NIH are now looking for other jobs. Officials emphasize that the new ethic rules will boost the agency’s credibility with the public. Certainly, with pharmaceutical companies attempting to exert influence both with researchers and doctors, NIH will gain integrity by steering clear from such monetary influence.
For the full article.